文献速递前列腺癌

Focal-One®局部前列腺HIFU消融的肿瘤学与功能结局:前瞻性单中心研究

Oncological and functional outcome after partial prostate HIFU ablation with Focal-One®: a prospective single-center study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-05-18

该前瞻性单中心研究纳入189例局限型前列腺癌患者,评估索引病灶HIFU消融的肿瘤学与功能结局。中位随访29个月,治疗失败率11.9%,PSA nadir较高和 anterior stroma 癌与失败风险增加相关,排尿功能保留良好而性功能轻度下降。

要点

  • 索引病灶HIFU消融早期肿瘤学结局可接受,但前部肿瘤消融不充分。
  • 较高的PSA nadir与治疗失败风险增加74%相关(OR 1.74)。
  • 前部间质癌使失败风险增加约三倍(OR 3.36)。

核心结论

  • 索引病灶HIFU消融显示满意的早期肿瘤学结局,但前部肿瘤消融不充分。
  • 排尿功能保留良好,性功能在随访期间轻度下降。

研究设计与样本

  • 前瞻性单中心研究,2017至2019年纳入189例未治疗局限型前列腺癌患者。
  • 纳入标准为cT≤2、预期寿命≥5年、grade group≤3;消融前均行多参数磁共振。
  • 前列腺体积≥80 ml者先行减容术。
  • 治疗失败定义为组织学证实肿瘤需挽救治疗或雄激素剥夺治疗。

主要发现

  • 中位年龄70(IQR 11)岁,基线PSA中位5.8(IQR 3)ng/ml。
  • 14例(7.4%)消融前接受前列腺减容术。
  • 消融方式:靶向消融104例(55%)、扩大靶向消融45例(23.8%)、半腺消融31例(16.4%)、扩大半腺消融9例(4.8%)。
  • 中位靶向消融体积14(IQR 9)ml。
  • 90天内63/189例(33.3%)发生93起并发症,其中77/93(82.8%)为轻微(Clavien 1-2级),16/93(17.2%)为主要并发症(Clavien 3a级)。

关键数值与推荐

  • 纳入标准:cT≤2、预期寿命≥5年、grade group≤3。
  • 治疗失败定义:组织学证实肿瘤需挽救治疗或雄激素剥夺治疗。

临床怎么用

  • 索引病灶HIFU消融可用于选定局限型前列腺癌患者,但前部肿瘤需谨慎评估。
  • 术后PSA nadir较高者应加强监测,因其与治疗失败风险增加相关。
  • 患者咨询时应告知排尿功能保留较好但性功能可能轻度下降。

局限性

  • 单中心前瞻性研究,样本量有限(189例)。
  • 中位随访仅29个月,早期肿瘤学结局需长期验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to evaluate oncological and functional outcomes of index lesion HIFU ablation with Focal-One®. MATERIALS AND METHODS: We prospectively assessed treatment-naïve men with localized prostate cancer between 2017 and 2019. Inclusion criteria were stage cT ≤ 2, ≥5 years of life expectancy, grade group ≤3. Multiparametric magnetic resonance was performed before ablation. Patients with a prostate volume of ≥80 ml underwent debulking. Treatment failure was defined as a histologically confirmed tumor that required salvage treatment or androgen deprivation therapy. RESULTS: One hundred and eighty nine patients were enrolled. Data are presented as median and Interquartile Range (IQR). Median age was 70(11) years. Median baseline PSA was 5.8(3) ng/ml. Fourteen (7.4%) patients had prostate debulking before ablation. 104 (55%) patients underwent targeted ablation, 45 (23.8%) extended targeted ablation, 31 (16.4%) hemiablation, and 9 (4.8%) extended hemiablation. Median targeted ablated volume was 14(9) ml. Ninety-three complications occurred in 63/189 (33.3%) patients within 90 days. There were 77/93 (82.8%) minor (Clavien grade 1-2) and 16/93 (17.2%) major complications (Clavien grade 3a). Thirty-nine patients suffered from genito-urinary infections (Clavien grade 2). Fifteen patients required transurethral resection of the prostate/urethrotomy for recurrent urinary retention (Clavien grade 3a). One patient developed a recto-urethral fistula (Clavien grade 3a) and two long-lasting urinary incontinence. Median PSA nadir was 2.2(2.9) ng/ml. At a median follow-up of 29(15) months, 21/177 (11.9%) patients were treatment failures, 26 on monitoring, and 26 had a further ablation. Multivariable logistic regression found that failure patients had higher PSA (7.8 vs 5.7 ng/ml,p0.001) and double PSA nadir (4.8 vs 2.0 ng/ml, p < 0.001). Higher PSA nadir correlated with a 74% higher probability of failure (OR 1.74 95% CI 1.40-2.16). Cancer in the anterior stroma increased the odds of failure of three folds (OR 3.36 95% CI 1.18-9.53). Two mixed effect models (one for IPSS and one for IEEF-15) were estimated and they showed that time reaches the statistical significance coefficient only for the IEEF-15, meaning that subsequent evaluations of the indicators were significantly lower at each time point. CONCLUSIONS: Index lesion HIFU ablation demonstrated satisfactory early oncological outcome but anteriorly located tumors had inadequate ablation. Urinary function was well preserved. Sexual function slightly decreased during follow-up.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Dellabella M, Branchi A, Di Rosa M, et al. Oncological and functional outcome after partial prostate HIFU ablation with Focal-One®: a prospective single-center study. Prostate Cancer Prostatic Dis. 2021. PMID: 34007021. doi:10.1038/s41391-021-00390-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。